Introduction {#Sec1}
============

ATP-binding cassette transporter subfamily G member 2 (ABCG2) is located in a gout-susceptibility locus on chromosome 4q, which was identified by previous studies including genome-wide association studies of serum uric acid levels \[[@CR1], [@CR2]\]. ABCG2 is a high-capacity urate exporter in the kidney and intestine, the dysfunction of which increases the risk for gout and hyperuricemia \[[@CR3]--[@CR6]\]. Since uric acid, the final product of purine metabolism, is mainly excreted by the kidneys, hyperuricemia is a common condition in patients with kidney failure \[[@CR7], [@CR8]\]. In addition, hyperuricemia is a risk factor for cardiovascular disease (CVD) in the general population \[[@CR9], [@CR10]\]. Furthermore, a previous study reported that serum uric acid levels were dependent on ABCG2 polymorphisms \[[@CR3], [@CR6], [@CR11]\]. These results suggest that ABCG2 plays a prominent role in uric acid homeostasis.

We recently found that ABCG2 is a major transporter of the uremic toxin indoxyl sulfate \[[@CR12]\]. ABCG2-knockout mice had lower survival rates and higher plasma indoxyl sulfate levels during kidney dysfunction \[[@CR12]\]. In addition, several studies have also reported that ABCG2 plays an important role in stimulating inflammation and regulating autophagy \[[@CR13]−[@CR14]\]. ABCG2 dysfunction may affect clinical outcomes, such as all-cause mortality, through accumulation of uric acid and uremic toxins and acceleration of inflammation and suppression of autophagy. However, no studies have analyzed the associations between ABCG2 polymorphism and clinical outcomes. Dialysis patients are usually anuric, thus the effect of renal excretion on uremic toxins is relatively small. For the above reasons, it is necessary to evaluate the influence of ABCG2 dysfunction in the intestine on clinical outcomes of dialysis patients. The aim of the present study was to investigate the association between serum uric acid levels and mortality in hemodialysis patients and to clarify the effects of estimated ABCG2 function on serum uric acid levels and mortality.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

In this prospective multicenter cohort study, hemodialysis patients were recruited at the dialysis outpatient units of 15 medical institutions in Tokyo, Japan \[[@CR16], [@CR17]\]. Baseline visits for patient enrollment were conducted between May 1, 2011 and March 31, 2012, and enrolled patients were followed up to June 1, 2016. Patients were older than 20 years, had spent at least 3 months on dialysis therapy, and regularly received thrice-weekly hemodialysis (3--5 h/session). Patients with acute gastrointestinal bleeding, acute coronary syndrome, and liver dysfunction at baseline were excluded. The study protocol was reviewed and approved by the ethics committee of the Jikei Institutional Review Board at Jikei University School of Medicine (22-182 6359). This study was also approved by each participating institution's review board. All study procedures were in accordance with the Declaration of Helsinki and its revisions. Written informed consent was obtained from all patients prior to inclusion in the study.

Data collection {#Sec4}
---------------

Age, body mass index (BMI), sex, dialysis vintage, primary illness leading to kidney dysfunction, and past medical history were extracted from medical records. Medication information (use of anti-hyperuricemic drugs including allopurinol and febuxostat, antiplatelet drugs, vitamin K antagonists, phosphate binders, vitamin D receptor agonists, cinacalcet, antihypertensive medications, and statins) was obtained from prescription records. Comorbidities and medications were determined by chart review and standardized interviews at baseline.

Blood samples were collected at study entry, before the hemodialysis session conducted after the longest inter-dialysis period. Routine biochemical measurements included serum creatinine, uric acid, sodium, potassium, phosphorus, calcium, serum albumin, blood urea nitrogen (BUN), alkaline phosphatase, hematocrit, intact parathyroid hormone (PTH), and C-reactive protein (CRP) levels. The delivered dialysis dose was measured by single pool Kt/V.

Outcomes {#Sec5}
--------

Clinical outcomes were prospectively recorded and coded, and blinded from clinical and biochemical data. This information was collected by study investigators. After review of the available information, the cause of death was classified as CVD, infectious disease, malignancy, or other. The primary outcome was all-cause mortality. In all analyses, follow-up was censored at loss to follow-up, renal transplantation, or the end of the study.

Statistical analysis {#Sec6}
--------------------

Non-normally distributed data are presented as medians (25th and 75th percentiles), and normally distributed data are summarized as means ± standard deviation (SD). Binary data are summarized as percentages. Differences between more than two groups were analyzed by analysis of variance or the Kruskal--Wallis test, as appropriate. Nominal variables were analyzed by the *χ*^2^ test. Patient characteristics were described by uric acid levels (quartiles). Serum uric acid levels were categorized by ABCG2 functions and use of anti-hyperuricemic drugs. To clarify the serum uric acid levels by ABCG2 functions, multiple regression analysis was used. Age, dialysis vintage, BMI, systolic blood pressure, diabetes mellitus, hemoglobin, albumin, BUN, creatinine, potassium, calcium, phosphorus, CRP, Kt/V, angiotensin covering enzyme inhibitors, angiotensin II receptor blockers, statins, antiplatelet drugs, and anti-hyperuricemic drugs were adopted as covariates.

Cox proportional hazard models were used to investigate the association between all-cause mortality and uric acid levels. Age, dialysis vintage, sex, diabetes mellitus, BMI, systolic blood pressure, hemoglobin, albumin, creatinine, potassium, calcium, phosphate, CRP, Kt/V, past history of CVD events, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, use of statins, use of vitamin D receptor agonists, use of antiplatelet drugs, and use of anti-hyperuricemic drugs were adopted as covariates. An adjusted restricted cubic spline curve with three knots was generated to show the non-linear association with all-cause mortality, and serum uric acid as a continuous variable was also examined using a fully adjusted model.

To investigate the association between ABCG2 function and all-cause mortality, Kaplan--Meier survival curves and log-rank tests were used, as well as a Cox proportional hazard model. Univariate and multivariate analyses are presented as \[hazard ratio (HR); 95% confidence interval (CI)\]. The following covariates were used for Cox proportional hazard models. Model I included age, dialysis vintage, sex, diabetes mellitus, BMI, systolic blood pressure, hemoglobin, albumin, creatinine, potassium, calcium, phosphate, CRP, Kt/V, past history of CVD, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, use of statins, use of vitamin D receptor agonists, and use of antiplatelet drugs. Model II included all covariates of Model I, uric acid, and use of anti-hyperuricemic drugs. Significance was set at *P* \< 0.05. All statistical analyses were performed using STATA 13.0 (STATA Corp., College Station, TX, USA).

Genetic analysis and assessment of ABCG2 function {#Sec7}
-------------------------------------------------

Genomic DNA was extracted from whole peripheral blood cells. Genotyping of ABCG2 dysfunctional variants (Q126X and Q141K) was performed using the TaqMan method (Life Technologies Corporation, Carlsbad, CA, USA) with a Light Cycler 480 (Roche Diagnostics, Mannheim, Germany), as previously described \[[@CR11], [@CR18]\]. Custom TaqMan assay probes were designed as follows: for Q126X, VIC-CCACTAATACTTACTTGTACCAC and FAM-CCACTAATACTTACTTATACCAC; and for Q141K, VIC-CTGCTGAGAACTGTAAGTT and FAM-CTGCTGAGAACTTTAAGTT.

To confirm their genotypes, DNA sequencing analysis was performed with the following primers: for Q126X, forward 5′-TGTACAATGAAAAGAGAAAGGTGAG-3′ and reverse 5′-CTGCCTTTTCACATAAGTGTC-3′; and for Q141K, forward 5′-ATGGAGTTAACTGTCATTTGC-3′ and reverse 5′-CACGTTCATATTATGTAACAAGCC-3′. PCR products were sequenced with the ABI PRISM 3700 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). We previously reported that Q126X is a nonfunctional variant, Q141K is a half-functional variant for urate excretion compared to the wild-type, and there was no simultaneous presence of the minor alleles of Q126X and Q141K in one haplotype \[[@CR3], [@CR5]\]. Thus, three haplotypes were defined as \*1 (126Q and 141Q), \*2 (126Q and 141 K), and \*3 (126X and 141Q), and all patients could be divided into the following ABCG2 functional groups: full function (\*1/\*1), 3/4 function (mild dysfunction, \*1/\*2), 1/2 function (moderate dysfunction, \*1/\*3 or \*2/\*2), and ≤ 1/4 function (severe dysfunction, \*2/\*3 or \*3/\*3) \[[@CR18]\].

Results {#Sec8}
=======

Patient characteristics categorized by serum uric acid levels {#Sec9}
-------------------------------------------------------------

A total of 1214 hemodialysis patients were evaluated and divided into quartiles according to serum uric acid levels (Table [1](#Tab1){ref-type="table"}). Significantly higher age and lower levels of BMI, serum BUN, serum creatinine, and serum phosphate were observed in patients with low serum uric acid levels. The prevalence of anti-hyperuricemic drug use was significantly higher in the low uric acid level group. In addition, a past history of CVD was more common in patients with low serum uric acid levels. On the other hand, there were no significant differences in dialysis vintage, CRP, and use of antiplatelet drugs among the four groups.Table 1Patient characteristicsSerum uric acid level (mg/dl)Quartile 1Quartile 2Quartile 3Quartile 4*P* valueUA \< 6.86.8 ≤ UA \< 7.67.6 ≤ UA \< 8.5UA ≥ 8.5Number297332273312Age (years)67 (11.5)64 (11.2)63 (10.9)60 (12.2) \< 0.001Male (%)212 (71.4)236 (71.1)182 (66.7)218 (69.9)0.6Dialysis vintage (months)80 (34--151)88 (40--165)85 (42--140)93 (43--149)0.14Diabetes mellitus (%)139 (46.8)114 (34.3)106 (38.8)101 (32.4) \< 0.001Body mass index (kg/m^2^)21.2 (4.5)21.0 (5.2)22.2 (5.1)22.6 (5.1) \< 0.001sBP (mmHg)153 (23)152 (22)151 (21)152 (21)0.64dBP (mmHg)78 (14)80 (13)80 (15)80 (14)0.07Hemoglobin (g/dl)10.3 (1.0)10.5 (1.0)10.5 (1.0)10.6 (1.1)0.02Albumin (g/dl)3.69 (0.34)3.76 (0.36)3.77 (0.33)3.81 (0.36) \< 0.001Blood urea nitrogen (mg/dl)58 (13)63 (14)67 (13)72 (13) \< 0.001Creatinine (mg/dl)10.4 (2.6)11.4 (2.9)11.8 (3.0)12.7 (3.4) \< 0.001Sodium (mEq/l)139 (3)139 (3)139 (3)139 (3)0.32Potassium (mEq/l)4.92 (0.71)5.02 (0.74)5.03 (0.69)5.02 (0.67) \< 0.001ALP (IU/l)225 (176--284)213 (171--271)221 (176--282)212 (168--276)0.03Calcium (mg/dl)8.9 (0.6)8.9 (0.7)8.9 (0.6)8.9 (0.6)0.95Phosphate (mg/dl)5.0 (1.2)5.4 (1.4)5.6 (1.4)5.8 (1.4) \< 0.001Magnesium (mg/dl)2.6 (0.5)2.6 (0.4)2.6 (0.4)2.6 (0.5)0.57iPTH (pg/ml)134 (82--209)140 (79--232)148 (80--205)168 (100--261) \< 0.001C-reactive protein (mg/dl)0.1 (0.05--0.32)0.1 (0.05--0.3)0.1 (0.05--0.5)0.1 (0.06--0.38)0.27Kt/V1.4 (0.7)1.4 (0.3)1.4 (0.3)1.4 (0.3)0.52Anti-hyperuricemic drug (%)64 (21.6)56 (16.9)46 (16.9)32 (10.3) \< 0.001Antiplatelet drug (%)152 (51.2)155 (16.7)137 (50.2)135 (43.3)0.2Anticoagulant drug (%)24 (8.1)32 (9.6)15 (5.5)21 (6.7)0.25ACE-I or ARB (%)155 (53.3)160 (49.5)122 (45.7)161 (53.1)0.23Statin (%)92 (31)80 (24.1)74 (27.1)67 (21.5)0.05Past history Cardiovascular disease (%)66 (22.2)52 (15.7)61 (22.3)43 (13.8)0.01 Malignancy (%)70 (23.6)56 (16.9)38 (13.9)38 (12.2) \< 0.001Data are means (SD), N (%), or medians (interquartile range) as appropriate*UA* uric acid, *sBP* systolic blood pressure, *dBP* diastolic blood pressure, *ALP* alkaline phosphatase, *iPTH* intact parathyroid hormone, *ACE-I* angiotensin-converting enzyme inhibitor, *ARB* angiotensin II receptor blocker

Serum uric acid levels and mortality {#Sec10}
------------------------------------

During the follow-up period, 220 deaths occurred. Details of the events were as follows: CVD events 114; infectious diseases 52; malignancies 33; and others 21. Cox proportional hazard models were used to analyze the association between mortality and serum uric acid levels. All-cause mortality was significantly higher in the group with the lowest serum uric acid level, relative to the other groups in unadjusted models (HR 1.94, 95% CI 1.33--2.81, *P* ≤ 0.001) and fully adjusted models (HR 1.89, 95% CI 1.14--3.10, *P* ≤ 0.001) (Table [2](#Tab2){ref-type="table"}). There were no significant differences among other groups. The restricted cubic spline curve of serum uric acid levels also showed an increased risk of mortality with decreased serum uric acid levels (Fig. [1](#Fig1){ref-type="fig"}).Table 2Cox hazard regression analysis for all-cause mortality by serum uric acid levelSerum uric acid level (mg/dl)Quartile 1Quartile 2Quartile 3Quartile 4UA \< 6.86.8 ≤ UA \< 7.67.6 ≤ UA \< 8.5UA ≥ 8.5Number297332273312Number of events (*n*)80554243Unadjusted HR (95% CI)1.94 (1.33--2.81)1.08 (0.72--1.61)1.0 (Reference)0.89(0.58--1.36)*P*value \< 0.0010.710.61Adjusted HR (95% CI)1.89 (1.14--3.10)1.21 (0.70--2.06)1.0 (Reference)1.21(0.70--2.10)*P*value \< 0.0010.70.15Adjusted for age, dialysis vintage, sex, diabetes mellitus, body mass index, systolic blood pressure, hemoglobin, albumin, creatinine, potassium, calcium, phosphate, c-reactive protein, Kt/V, past history of cardiovascular disease event, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, use of statins, use of vitamin D receptor agonists, use of anti-platelet drugs, and use of anti-hyperuricemic drugs*UA* uric acid, *HR* hazard ratio, *CI* confidence intervalFig. 1Restricted cubic spline curve of serum uric acid levels for all-cause mortality. The spline model has three degrees of freedom. The multivariate model includes age, dialysis vintage, sex, diabetes mellitus, body mass index, systolic blood pressure, hemoglobin, albumin, creatinine, potassium, calcium, phosphate, C-reactive protein, *Kt*/*V*, past history of cardiovascular disease events, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, use of statins, use of vitamin D receptor agonists, use of antiplatelet drugs, and use of anti-hyperuricemic drugs. The solid line shows the hazard ratio for mortality. Dotted lines show the 95% confidence interval of the hazard ratio. Lower levels of serum uric acid are associated with higher mortality

ABCG2 function types and serum uric acid levels {#Sec11}
-----------------------------------------------

The number of patients categorized by estimated ABCG2 function types was as follows: full function 568 (46.8%); 3/4 function 504 (41.5%); 1/2 function 129 (10.7%); and ≤ 1/4 function 13 (1.0%) (Table [3](#Tab3){ref-type="table"}). A set of important demographic and clinical data divided by ABCG2 function were included as seen in Supp 1. Serum uric acid levels were lowest in the full function group, and they gradually increased in accordance with the decrease in estimated ABCG2 function (mean ± SD, full function: 7.4 ± 1.2 mg/dl, 3/4 function: 7.9 ± 1.3 mg/dl, 1/2 function: 8.2 ± 1.4 mg/dl, ≤ 1/4 function: 8.7 ± 1.3 mg/dl, *P* ≤ 0.001) (Fig. [2](#Fig2){ref-type="fig"}a). Serum uric acid levels were also analyzed by estimated ABCG2 function categorized by anti-hyperuricemic drugs. In this study, 198 patients (16.3%) were prescribed anti-hyperuricemic drugs. As shown in Fig. [2](#Fig2){ref-type="fig"}b, c, the effect of estimated ABCG2 function was not modified by the use of anti-hyperuricemic drugs.Table 3Prevalence of estimated ABCG2 function types and genotype combinationsGenotype combinationNumber (%)Q126X(rs72552713)Q141K(rs2231142) ≤ 1/4 functionT/TC/C2 (0.1)T/CC/A11 (0.9)1/2 functionT/CC/C36 (3.0)C/CA/A93 (7.7)3/4 functionC/CC/A504 (41.5)Full functionC/CC/C568 (46.8)Total1214Fig. 2Serum uric acid levels by ABCG2 function and anti-hyperuricemic drug use. Associations between estimated ABCG2 function and serum uric acid levels are shown using all patients (**a**), non-users of anti-hyperuricemic drug (**b**), and anti-hyperuricemic drug users (**c**). The central box extends from the 25th to the 75th percentile. A center line within the box marks represents the median. Whiskers above and below the box indicate the 10th and 90th percentiles. All dots outside this range are outliers, which are not typical of the rest of the data. Statistical analysis was performed by analysis of variance

Using multiple linear regression analysis of uric acid levels with the dependent variables, estimated ABCG2 function was significantly associated with serum uric acid levels in the adjusted models (beta-coefficient ± SD, 3/4 function: 0.67 ± 0.08 *P* ≤ 0.001, 1/2 function: 1.05 ± 0.13 *P* ≤ 0.001, ≤ 1/4 function: 1.83 ± 0.36 *P* ≤ 0.001) (Table [4](#Tab4){ref-type="table"}).Table 4Association between serum uric acid levels and ABCG2 function types as determined by univariate and multivariate regression analysesABCG2 functionUric acid (mg/dl)Univariate analysisMultivariate analysisBeta coefficient*P* valueBeta coefficient*P* valueFull function7.4 ± 1.2RefRef3/4 function7.9 ± 1.30.47 ± 0.08 \< 0.0010.67 ± 0.08 \< 0.0011/2 function8.2 ± 1.40.83 ± 0.13 \< 0.0011.05 ± 0.13 \< 0.001 ≤ 1/4 function8.7 ± 1.31.29 ± 0.36 \< 0.0011.83 ± 0.36 \< 0.001Adjusted for age, dialysis vintage, body mass index, systolic blood pressure, diabetes mellitus, hemoglobin, albumin, blood urea nitrogen, creatinine, potassium, calcium, phosphorus, C-reactive protein, Kt/V, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, statins, anti-platelet drugs, and, anti-hyperuricemic drugs

All-cause mortality and ABCG2 function {#Sec12}
--------------------------------------

During the study period, 220 patients died. The ABCG2 ≤ 1/4 function type showed a significantly higher mortality rate than the other function types with the log-rank test (*P* ≤ 0.001) (Fig. [3](#Fig3){ref-type="fig"}). The causes of death in patients with the ABCG2 ≤ 1/4 function type were CVD events 1, infection 3, and others 1. A Cox-proportional hazard analysis for all-cause mortality was also performed. In reference to the ABCG2 full-function type, the ≤ 1/4 function type was significantly associated with all-cause mortality in the unadjusted model (HR 2.55, 95% CI 1.04 to 6.28, *P* = 0.04) and the fully adjusted model including serum uric acid levels and use of anti-hyperuricemic drugs (HR 6.66, 95% CI 2.49 to 17.8, *P* ≤ 0.001) (Table [5](#Tab5){ref-type="table"}).Fig. 3Kaplan--Meier survival analysis for all-cause mortality. During the follow-up period, 220 deaths occurred. The ABCG2 ≤ 1/4 function type was associated with significantly higher mortality than the other ABCG2 geneTable 5Cox hazard regression analysis of ABCG2 function types with all-cause mortality in hemodialysis patientsUnadjusted modelModel IModel IIHR95% CI*P*valueHR95% CI*P*valueHR95% CI*P*valueABCG2 function Full functionRefRefRef 3/4 function1.000.78 to 1.330.9780.880.61 to 1.280.5040.970.67 to 1.420.890 1/2 function0.830.52 to 1.350.4700.580.29 to 1.160.1250.680.34 to 1.370.284 ≤ 1/4 function2.551.04 to 6.280.0405.221.97 to 13.7 \< 0.0016.662.49 to 17.8 \< 0.001Model I: Adjusted for age, dialysis vintage, sex, diabetes mellitus, body mass index, systolic blood pressure, hemoglobin, albumin, creatinine, potassium, calcium, phosphate, c-reactive protein, Kt/V, past history of cardiovascular disease event, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, statins, vitamin D receptor agonists, and anti-platelet drugsModel II: Model I + (uric acid + anti-hyperuricemic drugs)*HR* hazard ratio, *CI* confidence interval

Discussion {#Sec13}
==========

In this study, lower serum uric acid levels were found to be associated with all-cause mortality in patients on hemodialysis. Estimated ABCG2 function was also found to be associated with serum uric acid levels, and this association was not modified by the use of anti-hyperuricemic drugs. Furthermore, this is the first study to show that severe ABCG2 dysfunction (≤ 1/4 function type) was associated with higher mortality than the other function levels in hemodialysis patients. This result was independent of serum uric acid levels and the use of anti-hyperuricemic drugs.

It has been suggested that hyperuricemia is linked to hypertension, insulin resistance, and metabolic syndrome \[[@CR19]\]. Some studies have reported that hyperuricemia is a risk factor for CVD in the general population \[[@CR9], [@CR10]\]. However, whether or not hyperuricemia is a risk factor for CVD events and mortality in dialysis patients is controversial \[[@CR7], [@CR8], [@CR20]--[@CR22]\]. Recent studies reported that serum uric acid levels are positively correlated with already known laboratory nutritional markers (albumin, creatinine), body composition parameters, handgrip strength, and the geriatric nutritional risk index in hemodialysis patients \[[@CR23], [@CR24]\]. Although serum albumin levels, creatinine, and BMI were used as nutritional status indicators in the multivariate analysis of the present study, serum uric acid was significantly associated with mortality in the fully adjusted models. The present results indicated that serum uric acid levels reflect nutritional status, which is not evaluated by ordinary makers such as albumin. Because a previous study reported that serum uric acid remained a mortality risk factor after adjustment for nutritional markers, the normal protein catabolic rate (nPCR) \[[@CR24]\] or subjective global assessment (SGA) \[[@CR25]\], serum uric acid in dialysis patients is not regarded as a simple nutritional marker. Another mechanism of uric acid's protective effect is related to antioxidants in human biologic fluids \[[@CR26]\]. Although uric acid is reported to evoke oxidative stress thorough peroxynitrite and lipoprotein \[[@CR27], [@CR28]\], uric acid provides an antioxidant effect to reduce oxo-heme oxidant levels and protect erythrocytes from peroxidation \[[@CR29]\]. Because patients on dialysis have higher oxidative stress, uric acid may have an important antioxidant effect. However, there have been no interventional studies to investigate whether elevation of uric acid attenuates the mortality risk in dialysis patients. Future studies are needed to evaluate the association between uric acid and mortality.

Since ABCG2 is the main urate transporter in both the kidney and intestine \[[@CR3], [@CR5], [@CR11], [@CR18], [@CR30], [@CR31]\], previous studies reported that dysfunctional ABCG2 gene polymorphisms are associated with hyperuricemia by decreasing urate excretion \[[@CR3], [@CR32]\]. In addition, ABCG2 is also associated with the prevalence and onset of gout \[[@CR3], [@CR6]\]. About two-thirds of urate is excreted from the kidneys and about one-third from the intestines \[[@CR33]\]. ABCG2 knockout mice showed decreased intestinal excretion of uric acid \[[@CR5], [@CR34]\]. ABCG2-mediated intestinal urate excretion was also evidenced in a human study \[[@CR11]\]. The present results showed that serum uric acid levels differed according to the estimated levels of ABCG2 function in hemodialysis patients. These results indicated that because patients on hemodialysis are usually anuric, the differences in serum uric acid levels between ABCG2 functions might depend on intestinal excretion. A previous study also reported that serum uric acid levels in dialysis patients are affected by ABCG2 gene types \[[@CR11]\].

The present study is the first to show that ABCG2 dysfunction is associated with all-cause mortality in hemodialysis patients. In the supp 1, there are no significant differences between ABCG2 function and contributory factors for mortality such as, age, diabetes mellitus, BMI, albumin, BUN, creatinine, potassium, phosphate, and iPTH. In addition, although we set explanatory variables in Cox hazard regression analysis for all-cause mortality to include serum uric acid levels and anti-hyprturicemic drugs, the effects of ABCG2 function types for mortality significantly remained. According to the above results, we consider the effects of ABCG2 function for mortality are independent of serum uric acid levels. There are several possible mechanisms for the association between ABCG2 polymorphism and mortality. First, the ABCG2 transporter regulates not only uric acid, but also uremic toxins in chronic kidney disease (CKD) \[[@CR12]\]. Our recent study showed that ABCG2-knockout CKD mice had higher mortality and decreased indoxyl sulfate excretion in the kidney and intestine \[[@CR12]\]. Indoxyl sulfate is a protein-bound uremic toxin resulting from bacterial metabolism of dietary tryptophan and is reported to be associated with mortality in CKD and dialysis patients \[[@CR35]−[@CR36]\]. Since ABCG2 gene type was significantly associated with higher serum uric acid levels in the present study, indoxyl sulfate may also be higher in patients with ABCG2 ≤ 1/4 function; potentially accounting for the elevated mortality. Second, because ABCG2 is associated with inflammation, ABCG2 gene type may affect CVD events through inflammation. Gout is known as a risk factor for CVD and all-cause mortality \[[@CR38], [@CR39]\]. However, since a previous study showed that gout is significantly associated with CVD events even after adjustment for serum uric acid levels \[[@CR40]\], this finding suggested that gout and inflammation induce CVD events. ABCG2, which is reported to be associated with the onset of gout according to genetic analysis \[[@CR1], [@CR3], [@CR6]\], has an important role in inflammation through inhibition of oxidative stress and NF-κB \[[@CR13], [@CR41]\]. This mechanism is mediated by the role of ABCG2 in exporting urate, which affects pro-oxidants in the intracellular setting and inhibits promotion of mitochondrial dysfunction \[[@CR42]\]. Third, ABCG2 has been reported to play an important role in autophagy. ABCG2-overexpressing cell lines were more resistant to stressors such as nutrient deprivation and ionizing radiation. On the other hand, knockdown of ABCG2 reduced autophagic activity in resistant cells \[[@CR15]\]. In addition, nuclear factor E2-related factor 2 (Nrf2), a transcription factor involved in oxidative stress responses, is reported to be associated with ABCG2 expression \[[@CR43]\]. The activation of the Nrf2 pathway has a cardioprotective effect \[[@CR44]\], which may be mediated by NrF2-induced ABCG2 expression and its consequent promotion of autophagy.

The present study is the first to show that ABCG2 gene type is associated with serum uric acid levels and mortality in dialysis patients. Few studies have reported the associations between common gene variants and clinical outcomes including death in dialysis patients. For example, JAK3, which is a single nucleotide polymorphism (SNP) of the Janus kinase--signal transducer and activator of transcription (Jak-Stat) signal transduction pathway, was reported to be associated with CVD events in dialysis \[[@CR45]\]. To date, the Klotho gene \[[@CR46]\] and the VEGF gene \[[@CR47]\] have been reported to be associated with clinical outcomes in dialysis patients. The present study showed that the ABCG2 gene type with ≤ 1/4 function was associated with higher mortality and a hazard ratio higher than for other common gene variants. To predict mortality of dialysis patients, stratification of patients with genetic risk factors will be meaningful in the future.

This study has several limitations. First, since this was an observational study, no causal relationships between ABCG2 gene type and serum uric acid levels and all-cause mortality could be proven. Second, meal information was not investigated. Uric acid levels are influenced by daily meal consumption and nutritional status. Third, serum uric acid levels were measured only at baseline. Fourth, information about a past history of gout was lacking. Previous studies reported that gout is a risk factor for CVD events independent of serum uric acid levels. Fifth, serum indoxyl sulfate levels were not measured. Because a previous study reported that ABCG2 gene type is associated with sulfate levels \[[@CR12]\], a future study is needed to investigate the association between ABCG2 gene type and sulfate levels in patients with CKD.

In conclusion, low levels of serum uric acid were associated with higher mortality in hemodialysis patients. In addition, ABCG2 gene types were associated with serum uric acid levels and all-cause mortality in hemodialysis patients. A future prospective, interventional study is required to clarify the effects of ABCG2 function on serum uric acid levels and clinical events and to elucidate the underlying mechanisms.
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